Search

Wave Life Sciences Ltd. filed a Form 4 with the U.S. Securities and Exchange Commission on October 18, 2024. This filing is a statement of changes in beneficial ownership of securities, as required by the SEC for directors, officers, or owners of more than ten percent of a class of equity securities. The company's contact information is provided in the filing, and additional details about SEC filings can be found on the SEC's website. The document pertains to the biotechnology industry and highlights the importance of regulatory compliance in the business sector. [Extracted from the article]

Moleculin Biotech, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 17, 2024. This form is used to report material events or corporate changes important to investors. The company's contact information is located in Houston, Texas, and the filing can be accessed on the SEC's website. The document pertains to biopharmaceutical and healthcare biotechnology companies, falling under the SIC code 2834 for Pharmaceutical Preparations. [Extracted from the article]

The article discusses a recent SEC filing by Aldeyra Therapeutics, Inc. on October 21, 2024. The filing, known as Form 4, is a statement of changes in beneficial ownership of securities. This document is a requirement for directors, officers, or owners of more than ten percent of a class of equity securities registered under Section 12 of the '34 Act. Aldeyra Therapeutics, Inc. is a biopharmaceutical company based in Lexington, MA, focusing on drugs and therapies in the healthcare biotechnology sector. [Extracted from the article]

Lixte Biotechnology Holdings, Inc. recently filed a Form S-1 with the U.S. Securities and Exchange Commission on October 23, 2024. The company's SIC code is 2834, Pharmaceutical Preparations, and the filing included 7 documents. The basic registration form, Form S-1, is used to register securities for publicly-traded companies like Lixte Biotechnology Holdings, Inc. For more information on the SEC filing, visit https://www.sec.gov/Archives/edgar/data/1335105/0001493152-24-042114-index.html. [Extracted from the article]

Eloxx Pharmaceuticals, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 17, 2024. This form is used to report material events or corporate changes that are important to investors. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. The company's contact information is listed as 480 Arsenal Way, Suite 130, Watertown, MA 02472, with a phone number of 781-577-5300. [Extracted from the article]

Fate Therapeutics Inc. filed a Form SC 13G/A with the U.S. Securities and Exchange Commission on October 21, 2024. The company's SIC code is 2836, and the filing can be found on the SEC's website. This news article provides information on the SEC filing and highlights keywords such as Business, Health and Medicine, Biopharmaceutical Companies, and Healthcare Biotechnology Companies. [Extracted from the article]

Capricor Therapeutics, Inc. filed a Form 424B5 with the U.S. Securities and Exchange Commission on October 17, 2024. The filing pertains to a prospectus submitted under Rule 424(b)(5) and includes contact information for the company. This document is part of the formal process by which publicly-traded companies disclose financial information to the SEC. [Extracted from the article]

The article discusses a recent SEC filing by Tiziana Life Sciences Ltd, a biotechnology company based in London, England. The filing, known as Form 6-K, is used by foreign private issuers to provide required information to the public, foreign stock exchanges, or security holders. This formal document is not considered "filed" for Section 18 liability purposes and serves as the primary means of communication between annual reports for foreign private issuers. The SEC filing can be accessed for further information on the company's activities. [Extracted from the article]

Enanta Pharmaceuticals Inc. filed a Form SC 13G/A with the U.S. Securities and Exchange Commission on October 17, 2024. The company's SIC code is 2834, Pharmaceutical Preparations, and the filing can be found on the SEC's website. This formal document is a financial statement submitted by publicly-traded companies, and more information can be accessed through the provided link. The news article focuses on Enanta Pharmaceuticals Inc., business, SEC filings, biopharmaceutical companies, and healthcare biotechnology companies. [Extracted from the article]

Dyne Therapeutics, Inc. filed a Form 4 with the U.S. Securities and Exchange Commission on October 22, 2024. This filing is a statement of changes in beneficial ownership of securities, as required by the SEC for directors, officers, or owners of more than ten percent of a class of equity securities. The document provides contact information for Dyne Therapeutics, Inc. and can be accessed on the SEC's website for further details. [Extracted from the article]

Revance Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 18, 2024. This form is used to report material events or corporate changes that are important to investors. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. The company's contact information is located in Nashville, Tennessee, and the filing can be accessed on the SEC's website for further details. [Extracted from the article]

Minerva Neurosciences, Inc. filed a U.S. Securities and Exchange Commission (SEC) Form DEF 14A on October 22, 2024. The filing included 5 documents and is related to non-management definitive proxy statements, typically for an annual meeting. Minerva Neurosciences Inc. is a healthcare biotechnology company with a SIC code of 2834, Pharmaceutical Preparations, based in Waltham, MA. [Extracted from the article]

Aprea Therapeutics, Inc. filed a Form 4 with the U.S. Securities and Exchange Commission on October 17, 2024, as reported by NewsRx. The filing pertains to changes in beneficial ownership of securities and is a standard requirement for directors, officers, or significant shareholders of publicly-traded companies. The document provides contact information for Aprea Therapeutics, Inc. and can be accessed on the SEC's website for further details. This news article focuses on business, SEC filings, drugs and therapies, and the healthcare biotechnology industry. [Extracted from the article]

Viking Therapeutics, Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on October 23, 2024. This form is a quarterly report that includes unaudited financial statements and provides insight into the company's financial position throughout the year. The filing is a formal document submitted by publicly-traded companies to the SEC, and it is essential for investors and stakeholders to understand the company's performance. [Extracted from the article]

A patent has been issued for hybrid drug delivery devices with a grip portion by Amgen Inc. The invention aims to address challenges faced by patients and caregivers when using autoinjectors and on-body injectors, focusing on simplifying the injection process. The drug delivery devices feature a housing with drug delivery components, a skin contact surface, a needle guard, and a retention portion designed to grip the user's skin. The patent provides detailed descriptions and claims for the innovative drug delivery device. [Extracted from the article]

AstraZeneca AB has been issued a patent for GLP-1 receptor ligand moiety conjugated oligonucleotides and their uses. The patent involves compounds and methods for modulating the expression of a nucleic acid target in cells expressing GLP-1 receptor, particularly in pancreatic beta islet cells. The patent details the structure of the compounds and their potential applications in targeting specific cells expressing GLP-1 receptor. [Extracted from the article]

A recent report by investigators at ImmunoGen Inc. in Waltham, Massachusetts, focused on assessing the immunogenicity of mirvetuximab soravtansine (MIRV) in patients with folate receptor alpha-positive ovarian cancer. The study involved the development and validation of assays to detect antidrug antibodies (ADAs) and neutralizing anti-MIRV antibodies (NAbs) in 734 patients across four clinical studies. The findings indicated low immunogenicity of MIRV, with limited data suggesting a potential association between ADAs and decreased efficacy. The validated assays will be used to monitor MIRV immunogenicity in future clinical trials. [Extracted from the article]

Microbot Medical Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 11, 2024. The filing pertains to material events or corporate changes important to investors. The company's SIC code is 3841, and the contact information is located in Hingham, MA. This filing provides current information on specified events for publicly-traded companies in the healthcare biotechnology sector. [Extracted from the article]

Microbot Medical Inc. filed a Form 424B3 with the U.S. Securities and Exchange Commission on October 15, 2024. The company operates in the healthcare biotechnology sector, with a focus on surgical and medical instruments and apparatus. The filing is a final prospectus submitted in accordance with Rule 424(b)(3) and can be accessed on the SEC's website for further details. [Extracted from the article]

The article discusses a recent SEC filing by Edwards Lifesciences Corp., a company in the biotechnology and life sciences industry. The filing, posted on October 15, 2024, pertains to changes in beneficial ownership of securities. The document provides contact information for the company and explains the purpose of SEC filings in relation to equity securities. Readers interested in further details can access the full filing on the SEC's website. [Extracted from the article]

Microbot Medical Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 15, 2024. The filing pertains to material events or corporate changes important to investors. The company's contact information is located in Hingham, MA, and the SEC file number is 0001493152-24-041048. This filing provides current information on specific events for publicly-traded companies in the healthcare biotechnology sector. [Extracted from the article]

Immunexpress, Pty Ltd., a molecular diagnostics company, published a study in the Journal of Clinical Medicine demonstrating the clinical utility of SeptiCyte RAPID in identifying sepsis in diverse patient populations. The test effectively discriminated between sepsis and SIRS across different races, medical conditions, and therapeutic regimens, allowing for individualized treatments. SeptiCyte RAPID performed well in identifying septic shock in patients from various racial groups and underlying disease states, showing consistent performance across different patient subgroups. This research highlights the importance of phenotypic stratification in categorizing sepsis patients based on clinical severity for appropriate therapeutic interventions. [Extracted from the article]

Boehringer Ingelheim has expanded its research and development facility in Athens, Georgia, with a capital investment of $66.1 million and the creation of 63 new jobs. This state-of-the-art facility is the company's largest animal health site in Georgia and third largest globally, focusing on innovation and improving animal health. The expansion was influenced by partnerships with local institutions and government agencies, reflecting a commitment to sustainability and community collaboration in advancing animal health research and innovation. [Extracted from the article]

A study conducted by AbbVie Inc. in Sugar Land, Texas, explores the use of covariate-adjusted response-adaptive randomization designs in clinical trials to achieve various objectives without model misspecification. The research proposes a new family of semiparametric approaches and utilizes target maximum likelihood estimation to analyze correlated data. Numerical studies show that this approach outperforms existing methods, even with complex data-generating distributions. The study was funded by the National Science Foundation and the University of Texas Health Science Center at Houston, and has been peer-reviewed. [Extracted from the article]

A recent study conducted by investigators at Genentech Inc. in South San Francisco, California, focused on the safety assessment of Protein A (PA) in biotherapeutics. PA, commonly used in affinity chromatography purification, was evaluated to establish a health-based exposure limit (HBEL) for patients. The research concluded that a parenteral HBEL of 1.2 µg/kg/dose is expected to be health protective when PA is present as an impurity in biotherapeutics. This peer-reviewed study provides valuable insights for the pharmaceutical industry regarding the safe use of PA in drug products. [Extracted from the article]

Researchers from Blueprint Medicines Corporation have identified and optimized STK17B kinase inhibitors that enhance T cell responses in vitro and in vivo, potentially offering a new approach for cancer immunotherapy. The study developed highly potent and selective small molecule inhibitors targeting STK17B, leading to increased T cell activation and antitumor activity in mouse models. This research highlights the potential of STK17B inhibition as a promising strategy for cancer treatment. [Extracted from the article]

A recent study conducted by researchers at Merck & Co. Inc. focused on the role of HIF-2A inhibition in adaptive immunity against kidney cancer growth. The study explored the impact of the HIF2A inhibitor belzutifan (MK-6482) in combination with immune checkpoint blockade therapy on T cell function and anti-tumor activity. Results from the study suggest that the combination treatment led to increased anti-tumor efficacy and T cell activation pathways, supporting further clinical evaluation of belzutifan and checkpoint blockade for renal cell carcinoma. The research was presented at the AACR Special Conference in Cancer Research, and the full article is available for free online. [Extracted from the article]

Centogene N.V. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 16, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their domicile country. The SEC filing is a formal document or financial statement submitted by publicly-traded companies. The SIC code for Centogene N.V. is 8071, Medical Laboratories. [Extracted from the article]

Oncocyte Corp. recently filed a Form S-3 with the U.S. Securities and Exchange Commission (SEC) on October 16, 2024. The company's SIC code is 2835, focusing on In Vitro and In Vivo Diagnostic Substances. This filing is a simplified registration form used by companies that have been reporting under the '34 Act for at least twelve months and have met timely filing requirements. More information on this SEC filing can be found on the SEC's website. [Extracted from the article]

Soleno Therapeutics Inc. filed a Form SC 13D/A with the U.S. Securities and Exchange Commission on October 10, 2024. The company's SIC code is 3845, and its contact information is located in Redwood City, CA. This SEC filing is a formal document submitted by publicly-traded companies, and more information can be found on the SEC's website. The article focuses on business, SEC filings, and biopharmaceutical companies, providing fact-based news on research and discoveries in the healthcare industry. [Extracted from the article]

Soleno Therapeutics Inc. filed a Form SC 13D/A with the U.S. Securities and Exchange Commission on October 15, 2024. The company's SIC code is 3845, and the filing includes contact information for Soleno Therapeutics Inc. This SEC filing is a formal financial statement submitted by publicly-traded companies. For more information, the full filing can be accessed on the SEC's website. [Extracted from the article]

Centogene N.V., a biopharmaceutical company in the healthcare biotechnology sector, filed a Form 6-K with the U.S. Securities and Exchange Commission on October 11, 2024. This filing is a formal document submitted by publicly-traded companies to provide information required to be made public in their domicile country or foreign stock exchanges where their securities are traded. The SEC filing can be accessed for more details at https://www.sec.gov/Archives/edgar/data/1757097/0001104659-24-108034-index.html. [Extracted from the article]

Oncocyte Corp. filed a Form 4 with the U.S. Securities and Exchange Commission on October 15, 2024. The filing pertains to changes in beneficial ownership of securities and is related to the company's SIC code 2835 for In Vitro and In Vivo Diagnostic Substances. Form 4 is required for directors, officers, or owners of more than ten percent of a class of equity securities registered under Section 12 of the '34 Act to report ownership information. The filing can be accessed on the SEC's website for further details. [Extracted from the article]

Oncocyte Corp. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 15, 2024. The filing pertains to material events or corporate changes important to investors and provides current information not previously reported. The company's SIC code is 2835, and the filing can be accessed on the SEC's website. This news article focuses on business, SEC filings, and healthcare biotechnology companies. [Extracted from the article]

Myriad Genetics Inc. filed a Form 4 with the U.S. Securities and Exchange Commission on October 10, 2024. This filing is related to changes in beneficial ownership of securities and is a standard procedure for publicly-traded companies. The document provides contact information for Myriad Genetics Inc. and explains the purpose of Form 4 in relation to equity securities. The filing can be accessed on the SEC website for further details. [Extracted from the article]

A patent was issued for a tube tray designed for handling secondary tubes in an automated processing system. The tray includes a base module and an insert for holding and dispensing secondary tubes in parallel. The tray aims to simplify the loading and unloading of secondary tubes in an automated system, providing a solution for introducing secondary tubes in an ordered and separable manner for further processing. The patent was filed by Roche Molecular Systems Inc. and published online on October 8, 2024. [Extracted from the article]

A patent was issued to Roche Diagnostics Operations Inc. for a method to classify identification tags on sample tubes in an automated laboratory system. The method aims to improve efficiency by predicting whether the identification tag can be recognized by laboratory devices. This innovation addresses issues such as deterioration of identification tags, ensuring accurate processing of samples in the laboratory system. [Extracted from the article]

Researchers from Pacific Biosciences of California Inc. utilized single-molecule sequencing to detect and size the C9orf72 repeat expansion, a common genetic cause of ALS and FTD. Traditional methods like PCR and Southern blot lack accuracy and sensitivity due to the region's GC-rich and repetitive content. This new approach allows for consistent and accurate sizing of repeat expansions, even for repeats in the thousands, without the need for amplification. The study was published in Bio-Protocol and can be accessed for free online. [Extracted from the article]

Jazz Pharmaceuticals announced positive results from a Phase 3 clinical trial evaluating Zepzelca in combination with atezolizumab for first-line maintenance therapy in extensive-stage small cell lung cancer patients. The combination showed statistically significant improvements in overall survival and progression-free survival compared to atezolizumab alone. The trial results suggest a potential advancement in treatment for patients with this aggressive form of lung cancer, with plans to submit for regulatory approval in 2025. [Extracted from the article]

Galmed Pharmaceuticals Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 15, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their domicile country or distributed to security holders. The SEC filing is a formal document submitted by publicly-traded companies, and more information can be found on the SEC website. The company's SIC code is 2834, Pharmaceutical Preparations, and their contact information is located in Ramat Gan, Israel. [Extracted from the article]

Acasti Pharma Inc. recently filed a Form EFFECT with the U.S. Securities and Exchange Commission (SEC) on October 16, 2024. The company operates in the pharmaceutical preparations industry, as indicated by its SIC code 2834. This SEC filing is a formal document submitted by publicly-traded companies, and more information can be found on the SEC's website. The news article focuses on business, SEC filings, and companies in the biopharmaceutical and healthcare biotechnology sectors. [Extracted from the article]

Theratechnologies Inc., a biopharmaceutical company, filed a Form 6-K with the U.S. Securities and Exchange Commission on October 10, 2024. This filing is a formal document submitted by publicly-traded companies to provide information required to be made public in their domicile country. The SEC file number for Theratechnologies Inc. is 0001193125-24-235639, and the company's contact information is located in Montreal. This report is essential for foreign private issuers to furnish information to the public between annual reports, as they are not required to file on Forms 10-Q or 8-K. [Extracted from the article]

Pfizer Inc. recently filed an SEC Form 3, the Initial Statement of Beneficial Ownership of Securities, on October 15, 2024. This filing is a formal document submitted to the U.S. Securities and Exchange Commission by publicly-traded companies like Pfizer Inc. The form contains information on ownership of equity securities and is a regulatory requirement for directors, officers, or owners of more than ten percent of a class of equity securities. The filing can be accessed on the SEC website for further details. [Extracted from the article]

Cocrystal Pharma, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 10, 2024. This form is used to report material events or corporate changes that are important to investors and have not been previously reported. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. The company's contact information is located in Bothell, WA, and the filing can be accessed on the SEC's website for further details. [Extracted from the article]

Redhill Biopharma Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 15, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their home country or distributed to shareholders. The SEC filing is a formal document submitted by publicly-traded companies, and more information can be found on the SEC's website. The company is located in Tel Aviv, and the filing pertains to pharmaceutical preparations. [Extracted from the article]

Akari Therapeutics Plc recently filed a Form EFFECT with the U.S. Securities and Exchange Commission (SEC) on October 15, 2024. The filing pertains to the company's activities in the biopharmaceutical sector, specifically in the field of drugs and therapies. This formal document is part of the regulatory requirements for publicly-traded companies like Akari Therapeutics Plc. For more details on the SEC filing, interested individuals can refer to the official SEC website. [Extracted from the article]

Benitec Biopharma Inc. filed a Form 424B5 with the U.S. Securities and Exchange Commission on October 15, 2024. The filing pertains to a prospectus submitted under Rule 424(b)(5) and includes contact information for the company based in Hayward, CA. This news article focuses on the business aspects of Benitec Biopharma Inc., highlighting its involvement in biopharmaceuticals and healthcare biotechnology. [Extracted from the article]

Promis Neurosciences Inc. recently filed a Form 8-K with the U.S. Securities and Exchange Commission on October 10, 2024. This filing is a "current report" used to disclose material events or corporate changes important to investors. The company's SIC code is 2834, Pharmaceutical Preparations, and the filing can be accessed on the SEC's website for further details. [Extracted from the article]

Maravai Lifesciences Holdings, Inc. filed a Form 4 with the U.S. Securities and Exchange Commission on October 16, 2024, as reported by NewsRx. The filing pertains to changes in beneficial ownership of securities and is a standard requirement for directors, officers, or owners of more than ten percent of a class of equity securities. The document provides contact information for the company and details the purpose and significance of SEC filings for publicly-traded companies in the biotechnology and life sciences sectors. [Extracted from the article]